Pharmacokinetic and pharmacodynamic considerations in gene therapy

被引:99
|
作者
Kamiya, H [1 ]
Akita, H [1 ]
Harashima, H [1 ]
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Mol Design Pharmaceut, Kita Ku, Sapporo, Hokkaido 0600812, Japan
关键词
D O I
10.1016/S1359-6446(03)02889-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During gene therapy the concentration of plasmid DNA or oligonucleotides in the plasma can be quite different from their concentrations in the nucleus or cytosol where they exert their actions. For a better understanding of the apparent discrepancies between pharmacokinetics (PK) and pharmacodynamics (PD), a new concept for intracellular PK with an emphasis on the final efficacy of gene transcription is needed. Here, the conventional PK and intracellular PK and PD of non-viral gene delivery systems are discussed, together with a new concept, referred to as controlled intracellular disposition, which integrates these factors to gain a better understanding of gene expression in the nucleus. The importance of optimizing the system from a transcriptional point of view in the nucleus is also discussed. These new concepts must be integrated to develop an optimized non-viral gene delivery system.
引用
收藏
页码:990 / 996
页数:7
相关论文
共 50 条
  • [21] Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins
    Iftekhar Mahmood
    Martin D. Green
    Clinical Pharmacokinetics, 2005, 44 : 331 - 347
  • [22] ANESTHESIA FOR THE AGED - SOME PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    MILLER, R
    MOUNT SINAI JOURNAL OF MEDICINE, 1987, 54 (04): : 305 - 307
  • [23] Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities
    Banach, Monika
    Poplawska, Monika
    Blaszczyk, Barbara
    Borowicz, Kinga K.
    Czuczwar, Stanislaw J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1067 - 1080
  • [24] Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
    Mahmood, I
    Green, MD
    CLINICAL PHARMACOKINETICS, 2005, 44 (04) : 331 - 347
  • [25] Use of opioids in the elderly - Pharmacokinetic and pharmacodynamic considerations
    Freye, E
    Levy, JV
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2004, 39 (09): : 527 - 537
  • [26] Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates
    Regazzi, Mario
    Berardi, Alberto
    Picone, Simonetta
    Tzialla, Chryssoula
    ANTIBIOTICS-BASEL, 2023, 12 (12):
  • [27] Warfarin withdrawal - Pharmacokinetic-pharmacodynamic considerations
    Palareti, G
    Legnani, C
    CLINICAL PHARMACOKINETICS, 1996, 30 (04) : 300 - 313
  • [28] Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness
    Mehrotra, R
    De Gaudio, R
    Palazzo, M
    INTENSIVE CARE MEDICINE, 2004, 30 (12) : 2145 - 2156
  • [29] Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness
    Rina Mehrotra
    Raffaele De Gaudio
    Mark Palazzo
    Intensive Care Medicine, 2004, 30 : 2145 - 2156
  • [30] Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
    Leipold, Douglas
    Prabhu, Saileta
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (02): : 130 - 139